Trials / Completed
CompletedNCT04165018
Prospective Study FNB, Is It Time To Abandon Cytological Assessment
Prospective Study FNB, Is It Time To Abandon Cytological Assessment (FACET)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Baylor College of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Endoscopic Ultrasound (EUS) is a minimally invasive procedure used by gastroenterologists to examine pancreatic masses and lesions. A fine needle is traversed through an endoscope and used to acquire tissue samples, which are then sent for pathology. The standard approach for diagnosing solid pancreatic lesions has been fine needle aspiration (FNA) (Han et al. 2016). However, the use of FNA comes with its limitations, some of which include multiple needle passes to acquire fluid, the need for on-site cytologists, and decreased diagnostic yield. Fine needle biopsy (FNB) is the latest approach being employed by endosonographers in lieu of FNA. FNB confers several advantages over FNB. First, FNB requires fewer needle passes than FNA to acquire tissue sample for immunohistochemical staining. In addition, FNB provides better tissues samples, greater sensitivity of the tissue core, and thus, improved diagnostic yields (Tian et al. 2018). Finally, FNB is more cost-effective than FNA and relies on pathologists, instead of on-site cytologists, and preserves the tissue core (Tian et al. 2018). The objective of this study is to establish a database of samples placed in formalin for patients who will undergo a fine-needle biopsy (FNB) for pathological evaluation without rapid on site cytological assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Fine-Needle Biopsy (FNB) | Fine-needle biopsy may be used to take samples of a pancreatic neoplasm. |
Timeline
- Start date
- 2021-04-09
- Primary completion
- 2023-04-06
- Completion
- 2023-10-10
- First posted
- 2019-11-15
- Last updated
- 2026-03-24
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04165018. Inclusion in this directory is not an endorsement.